Cargando…

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis

Macrophages are essential components of the human host immune system, which upon activation facilitates a broad pallet of immunomodulatory events including release of pro- or anti-inflammatory cytokines and chemokines, restoration of immune homeostasis and/or wound healing. Moreover, some macrophage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gantzel, Rasmus Hvidbjerg, Kjær, Mikkel Breinholt, Laursen, Tea Lund, Kazankov, Konstantin, George, Jacob, Møller, Holger Jon, Grønbæk, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820116/ https://www.ncbi.nlm.nih.gov/pubmed/33490096 http://dx.doi.org/10.3389/fmed.2020.615599

Ejemplares similares

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
por: Nielsen, Marlene Christina, et al.
Publicado: (2020)

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center
por: Laursen, Tea Lund, et al.
Publicado: (2022)

Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
por: Kazankov, Konstantin, et al.
Publicado: (2022)

The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients
por: Sandahl, Thomas Damgaard, et al.
Publicado: (2017)

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension
por: Ørntoft, Nikolaj Worm, et al.
Publicado: (2021)

No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
por: Kimer, Nina, et al.
Publicado: (2018)

Liver-related effects of chronic hepatitis C antiviral treatment
por: Laursen, Tea L, et al.
Publicado: (2020)

Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis
por: Svart, Mads, et al.
Publicado: (2018)

Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2022)

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
por: Kazankov, Konstantin, et al.
Publicado: (2020)

High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study
por: Björklund, Jessica, et al.
Publicado: (2018)

Monocyte Expression and Soluble Levels of the Haemoglobin Receptor (CD163/sCD163) and the Mannose Receptor (MR/sMR) in Septic and Critically Ill Non-Septic ICU Patients
por: Kjærgaard, Anders G., et al.
Publicado: (2014)

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
por: Laursen, Tea L, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study
por: Muhammad, Abdullah Ghassan, et al.
Publicado: (2022)

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson’s disease
por: Glavind, Emilie, et al.
Publicado: (2020)

The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis
por: Bossen, Lars, et al.
Publicado: (2023)

Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
por: Etzerodt, Anders, et al.
Publicado: (2017)

Macrophage activation marker sCD163 correlates with accelerated lipolysis following LPS exposure: a human-randomised clinical trial
por: Rittig, Nikolaj, et al.
Publicado: (2017)

Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis
por: Stilund, Morten, et al.
Publicado: (2014)

Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes
por: Svendsen, Pia, et al.
Publicado: (2016)

Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel
por: Stilund, Morten, et al.
Publicado: (2015)

Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease
por: Nissen, Sara Konstantin, et al.
Publicado: (2020)

Visceral obesity is associated with increased soluble CD163 concentration in men with type 2 diabetes mellitus
por: Sørensen, Lars Peter, et al.
Publicado: (2015)

Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case–control study
por: Knudsen, Andreas, et al.
Publicado: (2013)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
por: Nielsen, Mette J., et al.
Publicado: (2015)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
por: Kaji, Kosuke, et al.
Publicado: (2020)

Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer
por: Ding, Dongbing, et al.
Publicado: (2017)

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
por: Sherman, Kenneth E, et al.
Publicado: (2021)

Soluble CD163 is produced by monocyte-derived and alveolar macrophages, and is not associated with the severity of idiopathic pulmonary fibrosis
por: Chauvin, Pierre, et al.
Publicado: (2022)

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
por: Kawanaka, Miwa, et al.
Publicado: (2023)

No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation
por: Støy, Sidsel, et al.
Publicado: (2021)

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood
por: Krijgsman, Daniëlle, et al.
Publicado: (2020)

Soluble CD 163: A novel biomarker
por: Ahuja, Rajeev B.
Publicado: (2011)

Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
por: Mueller, Jessica L, et al.
Publicado: (2015)

Soluble haemoglobin scavenger receptor (sCD163): a marker associated with bacteraemia
por: Gaïni, S, et al.
Publicado: (2005)

Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
por: Laursen, Tea Lund, et al.
Publicado: (2022)

Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7kk21vc2ofvq9j63qcl4oc3qf3